Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...
Semaglutide medications including Ozempic and Wegovy have been shown to reduce kidney failure risk and the risk of death ...
On Tuesday, Vivani Medical Inc (NASDAQ:VANI) announced the publication of positive proof-of-concept weight loss data with OKV ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
The Laxxon weight loss tablet under the product identifier "LXM.2" is designed to provide patients with a non-invasive once-a ...
Novo Nordisk races against time and high demand to increase supply of Ozempic and Wegovy. There are only two places in the world where semaglutide is made.